In Massachusetts, Latest Annual Snapshot Shows a Tale of Two Biopharmas
The job contraction, according to MassBio, reflected pipeline reprioritization by biopharma giants plus contraction by smaller companies, with R&D jobs dropping significantly between Q2 and Q3 of 2025, then starting to bounce back by Q4. The mid-year drop explains last year’s overall 3.9% or 2,563-job decrease in R&D employment statewide, which fell to 62,991 from 65,554 jobs. The post In…
Massachusetts, home to the nation's leading biopharma cluster, presents a tale of two biopharmas in a new annual snapshot report by the Massachusetts Biotechnology Council (MassBio). While the state's life sciences sector is thriving in venture capital, IPOs, and M&A activity, recent trends paint a mixed picture.
Seed-stage venture capital funding dropped 39% in the first half of 2026 compared to the same period in 2025, falling from $7.65 million to $4.65 million. Additionally, NIH grant funding for research underpinning biopharma fell by 1.3%, from $3.458 billion to $3.413 billion, with a 6% decrease in the number of grants awarded - from 5,782 to 5,423.
The biopharma workforce in Massachusetts contracted by 3%, or 3,605 jobs, shrinking from 117,108 to 113,503. Ben Bradford, MassBio's head of external affairs, expressed concern over the declining number of "shots on goal" - fewer grants awarded for biopharma research. He added that MassBio is actively seeking additional NIH funding through discussions with Congressional delegations and building relationships with lawmakers from other states.
MassBio's Drive accelerator program, which partners with South Carolina's life-sci industry group SCbio, aims to support early-stage companies by providing them with industry expertise, mentorship, and connections. MassBio is also looking into providing non-dilutive grant funding to graduates of the program. However, the decline in biopharma jobs is attributed to pipeline reprioritization by large companies and contraction by smaller firms, with R&D employment decreasing by 3.9% statewide in 2025.
Among the 20 largest biopharma employers, eight showed year-over-year job declines, while two (Novartis and AstraZeneca/Alexion) showed no change. Takeda Pharmaceutical, the state's largest biopharma employer, reduced its Massachusetts headcount by 3% or 181 jobs, bringing the total to 5,628. Other companies, such as Eli Lilly, reported significant growth, with a 164% increase in headcount to 1,423 jobs.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
